Live video webcast with moderated fireside
chat with members from the CNS Pharmaceuticals management team and
featuring Key Opinion Leader, Samuel A.
Goldlust, MD, on Thursday, April
14th at 11:30 AM ET
HOUSTON, April 12,
2022 /PRNewswire/ -- CNS Pharmaceuticals,
Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a
biopharmaceutical company specializing in the development of novel
treatments for primary and metastatic cancers in the brain and
central nervous system, today announced it will participate in the
Virtual Investor Glioblastoma Multiforme (GBM) Spotlight event on
Thursday, April 14th at
11:30 AM ET.
For the spotlight event, John
Climaco, CEO of CNS Pharmaceuticals will be joined by Key
Opinion Leader Samuel A. Goldlust,
MD, to discuss GBM, the unmet need and the work CNS Pharmaceuticals
is doing to advance Berubicin for the treatment of recurrent
glioblastoma multiforme (GBM), one of the most aggressive types of
brain cancer.
Dr. Goldlust is a leading Neuro-Oncologist who currently serves
as the Pitkin Chair in Neuro-Oncology and Medical Director of the
Brain and Spine Institute, John Theurer Cancer Center and an
investigator in the Company's global potentially pivotal study of
Berubicin.
Berubicin is a novel anthracycline and the first anthracycline
to appear to cross the blood-brain barrier. Anthracyclines, a class
of anticancer agents that are among the most powerful chemotherapy
drugs and effective against more types of cancer than any other
class of chemotherapeutic agents, are designed to utilize natural
processes to induce deoxyribonucleic acid (DNA) damage in targeted
cancer cells by interfering with the action of topoisomerase II, a
critical enzyme enabling cell proliferation. Berubicin treatment of
brain cancer patients appeared to demonstrate positive responses
that include one durable complete response in a Phase 1 human
clinical trial conducted by Reata Pharmaceuticals, Inc. Berubicin,
was developed by Dr. Waldemar
Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Center. The
Company is currently conducting a potentially pivotal global study
evaluating the efficacy and safety of Berubicin in the treatment of
GBM.
A live video webcast of the presentation will be available
on the Events page of the Investors section of the
Company's website (cnspharma.com). A webcast replay will be
available two hours following the live presentation and will be
accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its
WP1244 drug technology portfolio, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is evaluating the use of WP1244 in the treatment of
brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Company's
cash runway to extend until Q1 2022 and the timing of patient
dosing to commence. These statements relate to future events,
future expectations, plans and prospects. Although CNS believes the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. CNS has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties and
other factors, including those discussed under Item 1A. "Risk
Factors" in CNS's most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in its Form 10-Q filings and in its other public filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of its date. CNS undertakes no obligation to
update any forward-looking statements contained in this press
release to reflect events or circumstances occurring after its date
or to reflect the occurrence of unanticipated events.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-the-virtual-investor-glioblastoma-multiforme-gbm-spotlight-event-301523574.html
SOURCE CNS Pharmaceuticals, Inc.